CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and future healthcare ethics.

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie ...

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Coronary heart disease is an ischemic condition characterized by vascular stenosis or obstruction caused by coronary atherosclerosis, resulting in myocardial ischemia, hypoxia, or necrosis. It is one ...

Coronary heart disease (CHD), characterized by atherosclerosis-induced myocardial ischemia, remains a leading cause of mortality in China. Safflower ...

In this article, you’ll find some of the top content that was published on LCGC this week, including an ASMS 2025 retrospective and an overview of microplastic research.

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.

The most common type of cholesterol-lowering drugs are statins, with brand names like Lipitor and Crestor. These work by ...

AstraZeneca has announced a sweeping $50 billion investment across the United States through 2030, marking the company’s largest commitment to U.S. pharmaceutical operations to date. The move signals ...